Steven E Schild

List of Publications by Year in Descending Order

490 papers	20,225 citations	68 h-index	131 g-index
507 ext. papers	23,385 ext. citations	3.1 avg, IF	6.47 L-index

#	Paper	IF	Citations
490	Biologically Effective Dose and Rectal Bleeding in Definitive Proton Therapy for Prostate Cancer.. *International Journal of Particle Therapy*, **2022**, 8, 37-46	1.5	
489	Gastroesophageal reflux disease and paraneoplastic neurological syndrome associated with long-term survival in limited stage small-cell lung cancer.. *Thoracic Cancer*, **2022**,	3.2	1
488	Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer.. *Anticancer Research*, **2022**, 42, 1973-1977	2.3	
487	Empirical Relative Biological Effectiveness (RBE) for Mandible Osteoradionecrosis (ORN) in Head and Neck Cancer Patients Treated With Pencil-Beam-Scanning Proton Therapy (PBSPT): A Retrospective, Case-Matched Cohort Study.. *Frontiers in Oncology*, **2022**, 12, 843175	5.3	1
486	Risk Factors for Sleep Problems Prior to Radiochemotherapy for Malignant Gliomas.. *In Vivo*, **2022**, 36, 325-329	2.3	0
485	Prognostic Factors of Survival After Radiotherapy for Lung Cancer-The Impact of Smoking Pack Years.. *In Vivo*, **2022**, 36, 1297-1301	2.3	
484	Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers.. *Anticancer Research*, **2022**, 42, 2657-2663	2.3	
483	Prognostic Value of Preclinical Markers after Radiotherapy of Metastatic Spinal Cord Compression—An Additional Analysis of Patients from Two Prospective Trials. *Cancers*, **2022**, 14, 2547	6.6	0
482	Sleep Disturbances in Lung Cancer Patients Assigned to Definitive or Adjuvant Irradiation. *In Vivo*, **2021**, 35, 3333-3337	2.3	
481	Consensus Statement on Proton Therapy in Mesothelioma. *Practical Radiation Oncology*, **2021**, 11, 119-133	2.8	4
480	Karnofsky Performance Score - An Independent Prognostic Factor of Survival After Palliative Irradiation for Sino-nasal Cancer. *Anticancer Research*, **2021**, 41, 2495-2499	2.3	0
479	Palliative Local Radiotherapy for Advanced Squamous Cell Carcinoma of the Head-and-Neck: Prognostic Factors of Survival. *Anticancer Research*, **2021**, 41, 3205-3210	2.3	
478	Dose-volume histogram parameters and patient-reported EPIC-Bowel domain in prostate cancer proton therapy. *Radiation Oncology Journal*, **2021**, 39, 122-128	2.5	
477	Technical Note: 4D robust optimization in small spot intensity-modulated proton therapy (IMPT) for distal esophageal carcinoma. *Medical Physics*, **2021**, 48, 4636-4647	4.4	0
476	EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA. *Neuro-Oncology*, **2021**, 23, i6-i6	1	78
475	A New Survival Score for Patients Scheduled for Palliative Irradiation of Locally Advanced Carcinoma of the Head-and-Neck. *Anticancer Research*, **2021**, 41, 3055-3058	2.3	0
474	Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT). *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 1189-1199	4	4

473	Technical Note: Multiple energy extraction techniques for synchrotron-based proton delivery systems may exacerbate motion interplay effects in lung cancer treatments. *Medical Physics*, **2021**, 48, 4812-4823	4.4	0
472	Impact of Cardiac Dose on Overall Survival in Lung Stereotactic Body Radiotherapy (SBRT) Compared to Conventionally Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). *Journal of Cancer Therapy*, **2021**, 12, 409-423	0.2	
471	Palliative Radiotherapy of Primary Glioblastoma. *In Vivo*, **2021**, 35, 483-487	2.3	2
470	Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer. *In Vivo*, **2021**, 35, 411-415	2.3	1
469	A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. *Anticancer Research*, **2021**, 41, 379-384	2.3	1
468	Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose. *Journal of Cancer Therapy*, **2021**, 12, 505-529	0.2	1
467	Comparison of 5 □□Gy and 10 □□Gy for metastatic spinal cord compression using data from three prospective trials. *Radiation Oncology*, **2021**, 16, 7	4.2	3
466	Proton beam radiotherapy for patients with early-stage and advanced lung cancer: a narrative review with contemporary clinical recommendations. *Journal of Thoracic Disease*, **2021**, 13, 1270-1285	2.6	1
465	Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy. *Anticancer Research*, **2021**, 41, 5165-5169	2.3	1
464	Sleep Disorders Prior to Adjuvant Radiation Therapy for Gynecological Malignancies. *Anticancer Research*, **2021**, 41, 4407-4410	2.3	1
463	Evaluation of Pre-radiotherapy Sleep Disorders in Patients With Rectal or Anal Cancer. *Anticancer Research*, **2021**, 41, 4439-4442	2.3	1
462	Risk Factors for Sleep Disturbances in Patients Scheduled for Radiotherapy of Head-and-Neck Cancer. *Anticancer Research*, **2021**, 41, 5065-5069	2.3	1
461	Sleep Disorders Before and During the COVID-19 Pandemic in Patients Assigned to Adjuvant Radiotherapy for Breast Cancer. *In Vivo*, **2021**, 35, 2253-2260	2.3	3
460	Accelerated Fractionation With Concomitant Boost . Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN). *Anticancer Research*, **2021**, 41, 477-484	2.3	
459	Accelerated Fractionation Plus Chemotherapy Conventionally Fractionated Radiochemotherapy for Unresectable Head-and-Neck Cancer. *Anticancer Research*, **2021**, 41, 877-884	2.3	0
458	Palliative Radiotherapy for Cutaneous Squamous Cell Carcinoma of the Head-and-Neck Region. *In Vivo*, **2021**, 35, 2283-2288	2.3	0
457	Emotional Problems Prior to Adjuvant Radiation Therapy for Breast Cancer. *In Vivo*, **2021**, 35, 2763-2770	2.3	1
456	Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617.. *Cancers*, **2021**, 13,	6.6	4

455	Prognostic Factors of Local Control and Survival in Patients Irradiated for Glioblastoma Multiforme (GBM). *Anticancer Research*, **2020**, 40, 7025-7030	2.3	1
454	Re-Irradiation for Recurrent Glioblastoma Multiforme. *Anticancer Research*, **2020**, 40, 7077-7081	2.3	3
453	Regarding Small Cell, Big Dilemma. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 865	4	
452	Clinical Prognostic Factors for Local Control and Survival After Irradiation of Grade II Gliomas. *In Vivo*, **2020**, 34, 3719-3722	2.3	1
451	Remaining Lifespan of Patients Aged ≥65 Years Receiving Whole-brain Irradiation for Metastases from Cancer of Unknown Primary. *Anticancer Research*, **2020**, 40, 2261-2264	2.3	1
450	Elderly Patients With Single Brain Metastasis - Overall Survival After Surgery Plus Whole-Brain Irradiation and a Radiation Boost. *In Vivo*, **2020**, 34, 1421-1425	2.3	1
449	Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2). *Strahlentherapie Und Onkologie*, **2020**, 196, 795-804	4.3	3
448	A Scoring Tool to Estimate the Survival of Elderly Patients With Brain Metastases from Esophageal Cancer Receiving Whole-brain Irradiation. *Anticancer Research*, **2020**, 40, 1661-1664	2.3	1
447	Seizures Prior to Whole-brain Irradiation for Metastatic Disease: Prevalence, Risk Factors and Association With Survival. *Anticancer Research*, **2020**, 40, 3429-3434	2.3	1
446	Extra-cerebral Metastasis - An Independent Predictor of Survival in Older Patients With Brain Metastases Receiving a Local Therapy Plus Whole-Brain Radiotherapy (WBRT). *Anticancer Research*, **2020**, 40, 2841-2845	2.3	1
445	Interval Between Cancer Diagnosis and Radiotherapy - An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer. *In Vivo*, **2020**, 34, 767-770	2.3	
444	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 631-640	4	26
443	Survival After Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT) for Cerebral Metastases in the Elderly. *In Vivo*, **2020**, 34, 1909-1913	2.3	1
442	Seizures Prior to Radiotherapy of Gliomas: Prevalence, Risk Factors and Survival Prognosis. *Anticancer Research*, **2020**, 40, 3961-3965	2.3	3
441	Robust Optimization for Intensity Modulated Proton Therapy to Redistribute High Linear Energy Transfer from Nearby Critical Organs to Tumors in Head and Neck Cancer. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 181-193	4	15
440	Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer. *In Vivo*, **2020**, 34, 679-682	2.3	1
439	A Disease-specific Score for Estimating Survival After Irradiation of Bone Metastases from Colorectal Cancer. *Anticancer Research*, **2020**, 40, 287-291	2.3	1
438	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. *Radiotherapy and Oncology*, **2020**, 146, 223-229	5.3	105

437	Individualisation of Radiation Therapy for Older Persons With Secondary Brain Lesions from Carcinoma of the Breast. *Anticancer Research*, **2020**, 40, 2271-2274	2.3	1
436	An Easy-To-Use Survival Score Compared to Existing Tools for Older Patients with Cerebral Metastases from Colorectal Cancer. *Cancers*, **2020**, 12,	6.6	1
435	Pre-Treatment Seizures in Patients With 1-3 Cerebral Metastases Receiving Local Therapies Plus Whole-brain Radiotherapy. *In Vivo*, **2020**, 34, 2727-2731	2.3	0
434	Re-Evaluation of Prognostic Factors for Survival After Radiotherapy of Cerebral Gliomas: A Supplementary Analysis to a Previous Study. *Anticancer Research*, **2020**, 40, 6513-6515	2.3	1
433	An Instrument to Guide Physicians when Estimating the Survival of Elderly Patients With Brain Metastasis from Gynecological Cancer. *Anticancer Research*, **2020**, 40, 2257-2260	2.3	2
432	Evaluation of Five Survival Scores in a Cohort of Elderly Patients With Cerebral Metastasis from Non-small Cell Lung Cancer. *Anticancer Research*, **2020**, 40, 2847-2851	2.3	1
431	Occurrence of Seizures Prior to Single-fraction Radiosurgery or Multi-fraction Stereotactic Radiotherapy in Patients With Very Few Brain Metastases. *Anticancer Research*, **2020**, 40, 3499-3504	2.3	1
430	A Simple Clinical Instrument to Predict the Survival Probability of Breast Cancer Patients Receiving Radiotherapy for Bone Metastases. *Anticancer Research*, **2020**, 40, 367-371	2.3	
429	Precision Radiation Therapy for Metastatic Spinal Cord Compression: Final Results of the PRE-MODE Trial. *International Journal of Radiation Oncology Biology Physics*, **2020**, 106, 780-789	4	8
428	Hybrid 3D analytical linear energy transfer calculation algorithm based on precalculated data from Monte Carlo simulations. *Medical Physics*, **2020**, 47, 745-752	4.4	11
427	An easy-to-use scoring system to estimate the survival of patients irradiated for bone metastases from lung cancer. *Translational Lung Cancer Research*, **2020**, 9, 1067-1073	4.4	2
426	Beam angle comparison for distal esophageal carcinoma patients treated with intensity-modulated proton therapy. *Journal of Applied Clinical Medical Physics*, **2020**, 21, 141-152	2.3	4
425	Intensity-modulated proton therapy (IMPT) interplay effect evaluation of asymmetric breathing with simultaneous uncertainty considerations in patients with non-small cell lung cancer. *Medical Physics*, **2020**, 47, 5428-5440	4.4	3
424	Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer. *Anticancer Research*, **2020**, 40, 1665-1668	2.3	1
423	Estimating the Lifespan of Elderly Patients With Cerebral Metastases from Kidney Cancer. *In Vivo*, **2020**, 34, 1321-1324	2.3	1
422	The Results of Whole-brain Radiotherapy for Elderly Patients With Brain Metastases from Urinary Bladder Cancer. *In Vivo*, **2020**, 34, 1317-1320	2.3	
421	Radiotherapy of Grade III Gliomas: Identification of Clinical Prognostic Factors for Local Tumor Control and Survival. *In Vivo*, **2020**, 34, 3627-3630	2.3	
420	Three-Dimensionally Printed On-Skin Radiation Shields Using High-Density Filament. *Practical Radiation Oncology*, **2020**, 10, e543-e550	2.8	3

419	Pre-operative Seizures in Patients With Single Brain Metastasis Treated With Resection Plus Whole-Brain Irradiation and a Boost. *In Vivo*, **2020**, 34, 2705-2709	2.3	1
418	Linear accelerator-based single-fraction stereotactic body radiotherapy for symptomatic vertebral body hemangiomas: The Mayo Clinic experience. *Journal of Clinical Neuroscience*, **2020**, 80, 74-78	2.2	2
417	Development of a multivariable prediction model to estimate the remaining lifespan of elderly patients with cerebral metastases from small-cell lung cancer. *Translational Lung Cancer Research*, **2020**, 9, 1433-1440	4.4	
416	A Simple Implement for Assessing the Survival of Elderly Patients With Melanoma Irradiated for Cerebral Metastases. *In Vivo*, **2020**, 34, 1361-1364	2.3	1
415	Detecting spatial susceptibility to cardiac toxicity of radiation therapy for lung cancer. *IISE Transactions on Healthcare Systems Engineering*, **2020**, 10, 243-250	1.3	2
414	Predicting the Risk of Subsequent Distant Brain Metastases After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients. *Anticancer Research*, **2020**, 40, 4081-4086	2.3	
413	Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience. *Advances in Radiation Oncology*, **2020**, 5, 450-458	3.3	8
412	Technical Note: Treatment planning system (TPS) approximations matter - comparing intensity-modulated proton therapy (IMPT) plan quality and robustness between a commercial and an in-house developed TPS for nonsmall cell lung cancer (NSCLC). *Medical Physics*, **2019**, 46, 4755-4762	4.4	7
411	Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis. *Radiotherapy and Oncology*, **2019**, 141, 56-61	5.3	41
410	The Search for Optimal Stereotactic Body Radiotherapy Dose in Inoperable, Centrally Located Non-Small-Cell Lung Cancer Continues. *Journal of Clinical Oncology*, **2019**, 37, 2697-2699	2.2	6
409	Patient-Reported Outcomes-Secondary Analysis of the SCORE-2 Trial Comparing 4 Gy □5 to 3 Gy □ 10 for Metastatic Epidural Spinal Cord Compression. *International Journal of Radiation Oncology Biology Physics*, **2019**, 105, 760-764	4	2
408	A randomized trial (RAREST-01) comparing Mepitel□ Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). *Radiotherapy and Oncology*, **2019**, 139, 79-82	5.3	6
407	Rational radiotherapy: The role in node-negative squamous cell carcinoma. *Journal of the American Academy of Dermatology*, **2019**,	4.5	
406	Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. *International Journal of Radiation Oncology Biology Physics*, **2019**, 103, 686-696	4	10
405	Impact of planned dose reporting methods on Gamma pass rates for IROC lung and liver motion phantoms treated with pencil beam scanning protons. *Radiation Oncology*, **2019**, 14, 108	4.2	1
404	Diagnosis-specific WBRT-30-CRC Score for Estimating Survival of Patients Irradiated for Brain Metastases from Colorectal Cancer. *Anticancer Research*, **2019**, 39, 2569-2574	2.3	3
403	Small-cell Lung Cancer in Very Elderly (□80 Years) Patients. *Clinical Lung Cancer*, **2019**, 20, 313-321	4.9	10
402	Estimating Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Whole-brain Radiotherapy With a New Tool. *Anticancer Research*, **2019**, 39, 2091-2095	2.3	4

401	Predictors of Outcomes and a Scoring System for Estimating Survival in Patients Treated With Radiotherapy for Metastatic Spinal Cord Compression From Small-Cell Lung Cancer. *Clinical Lung Cancer*, **2019**, 20, 322-329	4.9	5
400	Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses. *Anticancer Research*, **2019**, 39, 1343-1346	2.3	2
399	Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM. *Anticancer Research*, **2019**, 39, 1501-1505	2.3	3
398	A New Diagnosis-Specific Survival Score for Patients to be Irradiated for Brain Metastases from Non-small Cell Lung Cancer. *Lung*, **2019**, 197, 321-326	2.9	6
397	Prognostic Role of Pre-Treatment Symptoms for Survival of Patients Irradiated for Brain Metastases. *Anticancer Research*, **2019**, 39, 4273-4277	2.3	3
396	Clinical evaluation of fitness to drive in patients with brain metastases. *Neuro-Oncology Practice*, **2019**, 6, 484-489	2.2	1
395	A new instrument for predicting survival of patients with cerebral metastases from breast cancer developed in a homogeneously treated cohort. *Radiology and Oncology*, **2019**, 53, 219-224	3.8	3
394	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 1464-1472	7.3	324
393	Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases. *Cancers*, **2019**, 11,	6.6	6
392	Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients. *Anticancer Research*, **2019**, 39, 6217-6222	2.3	0
391	Prognostic factors and a new scoring system for survival of patients irradiated for bone metastases. *BMC Cancer*, **2019**, 19, 1156	4.8	2
390	Clinical Validation of a Ray-Casting Analytical Dose Engine for Spot Scanning Proton Delivery Systems. *Technology in Cancer Research and Treatment*, **2019**, 18, 1533033819887182	2.7	9
389	A novel and individualized robust optimization method using normalized dose interval volume constraints (NDIVC) for intensity-modulated proton radiotherapy. *Medical Physics*, **2019**, 46, 382-393	4.4	6
388	Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 298-303	8.9	10
387	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. *Cancer*, **2019**, 125, 382-390	6.4	9
386	Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic Experience. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2018**, 2, 40-48	3.1	11
385	Data collection of patient outcomes: one institution's experience. *Journal of Radiation Research*, **2018**, 59, i19-i24	2.4	1
384	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. *Journal of Thoracic Oncology*, **2018**, 13, 1171-1182	8.9	9

383	Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 479-489	4	26
382	Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 177-185	4	22
381	Fatal Radiation Pneumonitis in Patients With Subclinical Interstitial Lung Disease. *Clinical Lung Cancer*, **2018**, 19, e417-e420	4.9	8
380	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 807-821	7.3	314
379	A Tool to Predict the Probability of Intracerebral Recurrence or New Cerebral Metastases After Whole-brain Irradiation in Patients with Head-and-Neck Cancer. *Anticancer Research*, **2018**, 38, 4199-4202	2.3	7
378	1x8 Gy versus 5x4 Gy for metastatic epidural spinal cord compression: a matched-pair study of three prognostic patient subgroups. *Radiation Oncology*, **2018**, 13, 21	4.2	6
377	An Instrument for Estimating the 6-Month Survival Probability After Whole-brain Irradiation Alone for Cerebral Metastases from Gynecological Cancer. *Anticancer Research*, **2018**, 38, 3753-3756	2.3	11
376	Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with ≤2 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer. *Anticancer Research*, **2018**, 38, 3653-3656	2.3	0
375	Stereotactic Radiosurgery Alone for One to Two Brain Metastases from Cancer of Unknown Primary. *Anticancer Research*, **2018**, 38, 565-567	2.3	5
374	Predictive Factors for Local Control and Survival in Patients with Cancer of Unknown Primary (CUP) Irradiated for Cerebral Metastases. *Anticancer Research*, **2018**, 38, 2415-2418	2.3	4
373	Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial. *Anticancer Research*, **2018**, 38, 1009-1015	2.3	2
372	Metastatic Epidural Spinal Cord Compression: Conventional Radiotherapy **2018**, 159-176		
371	Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases. *In Vivo*, **2018**, 32, 381-384	2.3	7
370	A New Scoring-system for Estimating Overall Survival After Radiotherapy of Recurrent Head and Neck Cancers. *Anticancer Research*, **2018**, 38, 1611-1613	2.3	
369	Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer. *Anticancer Research*, **2018**, 38, 2391-2394	2.3	2
368	Predicting Survival After Whole-brain Irradiation for Cerebral Metastases in Patients with Cancer of the Bladder. *In Vivo*, **2018**, 32, 633-636	2.3	5
367	Predicting the Risk of Developing New Cerebral Lesions After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastases from Renal Cell Carcinoma. *Anticancer Research*, **2018**, 38, 2973-2976	2.3	3
366	A Score to Identify Patients with Brain Metastases from Colorectal Cancer Who May Benefit from Whole-brain Radiotherapy in Addition to Stereotactic Radiosurgery/Radiotherapy. *Anticancer Research*, **2018**, 38, 3111-3114	2.3	5

365	Robust optimization in IMPT using quadratic objective functions to account for the minimum MU constraint. *Medical Physics*, **2018**, 45, 460-469	4.4	11
364	A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression. *Radiation Oncology*, **2018**, 13, 257	4.2	3
363	Potential Prognostic Factors of Downstaging Following Preoperative Chemoradiation for High Rectal Cancer. *In Vivo*, **2018**, 32, 1481-1484	2.3	2
362	Prognostic Factors and a Survival Score in Patients Irradiated for Metastatic Epidural Spinal Cord Compression from Urothelial Carcinoma Cancer of the Bladder. *Anticancer Research*, **2018**, 38, 6841-6846	2.3	2
361	A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers. *Anticancer Research*, **2018**, 38, 6877-6880	2.3	3
360	Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Does the Interval Between Imaging and Treatment Matter?. *Anticancer Research*, **2018**, 38, 6835-6840	2.3	3
359	Outcomes After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients with Oligo-metastatic Breast Cancer. *Anticancer Research*, **2018**, 38, 6897-6903	2.3	3
358	Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study. *Journal of Applied Clinical Medical Physics*, **2018**, 19, 140-148	2.3	19
357	Role of Neoadjuvant Radio-chemotherapy for the Treatment of High Rectal Cancer. *Anticancer Research*, **2018**, 38, 5371-5377	2.3	4
356	A Specific Survival Score for Patients Receiving Local Therapy for Single Brain Metastasis from a Gynecological Malignancy. *In Vivo*, **2018**, 32, 825-828	2.3	11
355	A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases. *BMC Cancer*, **2017**, 17, 30	4.8	7
354	Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). *Journal of Thoracic Oncology*, **2017**, 12, 697-703	8.9	12
353	Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer. *Lung*, **2017**, 195, 217-224	2.9	28
352	GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer. *British Journal of Radiology*, **2017**, 90, 20170174	3.4	7
351	Exploratory study of the association of volumetric modulated arc therapy (VMAT) plan robustness with local failure in head and neck cancer. *Journal of Applied Clinical Medical Physics*, **2017**, 18, 76-83	2.3	29
350	Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 504-535	7.3	729
349	Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. *Clinical Genitourinary Cancer*, **2017**, 15, e969-e975	3.3	35
348	A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 1021-1025	4	6

347	Robust treatment planning with conditional value at risk chance constraints in intensity-modulated proton therapy. *Medical Physics*, **2017**, 44, 28-36	4.4	18
346	Robust intensity-modulated proton therapy to reduce high linear energy transfer in organs at risk. *Medical Physics*, **2017**, 44, 6138-6147	4.4	32
345	Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer. *Journal of Oncology Practice*, **2017**, 13, 732-738	3.1	14
344	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. *Journal of Clinical Oncology*, **2017**, 35, 2885-2892	2.2	48
343	Mixed integer programming with dose-volume constraints in intensity-modulated proton therapy. *Journal of Applied Clinical Medical Physics*, **2017**, 18, 29-35	2.3	5
342	A New Scoring Tool to Assess Overall Survival in Patients With Intracerebral Metastases From Gynecological Cancers. *International Journal of Gynecological Cancer*, **2017**, 27, 597-602	3.5	6
341	Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 1078-1082	4	15
340	A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases. *Radiation Oncology*, **2017**, 12, 69	4.2	9
339	Role of the overall treatment time of radiotherapy with 10 Gy for outcomes in patients with metastatic spinal cord compression. *Journal of Medical Imaging and Radiation Oncology*, **2017**, 61, 388-393	1.7	1
338	Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. *European Archives of Oto-Rhino-Laryngology*, **2017**, 274, 1021-1027	3.5	6
337	Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. *Journal of Clinical Oncology*, **2017**, 35, 56-62	2.2	373
336	Results of a multicenter study investigating the potential impact of the overall treatment time on outcomes of radiation therapy alone with 4 Gy for metastatic epidural spinal cord compression. *Practical Radiation Oncology*, **2017**, 7, 137-144	2.8	3
335	Prophylactic Cranial Irradiation Following Surgical Resection of Early-Stage Small-Cell Lung Cancer: A Review of the Literature. *Frontiers in Oncology*, **2017**, 7, 228	5.3	8
334	Survival Following Palliative External-beam Radiotherapy of Locally Advanced and Metastatic Liver Cancer. *Anticancer Research*, **2017**, 37, 203-206	2.3	1
333	Development of a Survival Score for Patients with Cerebral Metastases from Melanoma. *Anticancer Research*, **2017**, 37, 249-252	2.3	4
332	Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer. *Anticancer Research*, **2017**, 37, 1485-1488	2.3	3
331	Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer. *Anticancer Research*, **2017**, 37, 2693-2696	2.3	11
330	Factors Impacting the Overall Survival of Patients Irradiated for Invasive Carcinoma of the Urinary Bladder. *In Vivo*, **2017**, 31, 741-744	2.3	2

329	Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. *Journal of Cancer Therapy*, **2017**, 8, 73-85	0.2	13
328	Clinical Factors Asssociated with Treatment Outcomes following Whole-brain Irradiation in Patients with Prostate Cancer. *In Vivo*, **2017**, 31, 35-38	2.3	2
327	Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer. *In Vivo*, **2017**, 31, 117-120	2.3	1
326	A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer. *Anticancer Research*, **2017**, 37, 1481-1484	2.3	3
325	A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder. *In Vivo*, **2017**, 31, 435-438	2.3	2
324	Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly. *Anticancer Research*, **2017** , 37, 3287-3290	2.3	2
323	Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer. *Anticancer Research*, **2017**, 37, 2537-2540	2.3	
322	A New Prognostic Tool for Patients Undergoing Radiotherapy plus Upfront Transurethral Resection for Bladder Cancer. *In Vivo*, **2017**, 31, 745-748	2.3	2
321	A Survival Score Based on Symptoms and Performance Status for Patients with High-grade Gliomas Receiving Radiochemotherapy. *In Vivo*, **2017**, 31, 689-693	2.3	2
320	Radiosurgery with a Rotating Gamma System: A Very Effective Treatment for Symptomatic Cerebral Cavernomas. *Anticancer Research*, **2017**, 37, 3729-3733	2.3	2
319	Small Cell Lung Cancer **2016**, 798-808.e2		
318	Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. *OMICS Journal of Radiology*, **2016**, 5,	0	3
317	Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. *Journal of Cranio-Maxillo-Facial Surgery*, **2016**, 44, 1436-40	3.6	4
316	Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?. *Oral Oncology*, **2016**, 59, 67-72	4.4	8
315	Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. *Cancer Medicine*, **2016**, 5, 1890-6	4.8	14
314	Lung cancer: Best supportive care - a reasonable option for patients with brain metastases?. *Nature Reviews Clinical Oncology*, **2016**, 13, 722-724	19.4	
313	Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers. *BMC Cancer*, **2016**, 16, 437	4.8	16
312	Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy. *BJU International*, **2016**, 118, 236-42	5.6	2

311	Reply to D.E. Spratt and N. Szerlip. *Journal of Clinical Oncology*, **2016**, 34, 2677-8	2.2	
310	A Survival Score for Patients Receiving Palliative Irradiation for Locally Advanced Lung Cancer. *Clinical Lung Cancer*, **2016**, 17, 558-562	4.9	10
309	Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). *Journal of Thoracic Oncology*, **2016**, 11, 361-9	8.9	7
308	A predictive tool particularly designed for elderly myeloma patients presenting with spinal cord compression. *BMC Cancer*, **2016**, 16, 292	4.8	5
307	Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 505-516	4	99
306	RE: Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	
305	A Prognostic Instrument to Estimate the Survival of Elderly Patients Irradiated for Metastatic Epidural Spinal Cord Compression From Lung Cancer. *Clinical Lung Cancer*, **2016**, 17, 279-84	4.9	4
304	Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer. *Lung*, **2016**, 194, 295-8	2.9	7
303	Radiotherapy With 4 Gy □5 Versus 3 Gy □10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01). *Journal of Clinical Oncology*, **2016**, 34, 597-602	2.2	68
302	Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 523-533	4	78
301	An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer. *PLoS ONE*, **2016**, 11, e0151785	3.7	1
300	Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers. *Anticancer Research*, **2016**, 36, 4777-80	2.3	3
299	Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer. *Anticancer Research*, **2016**, 36, 4817-9	2.3	1
298	A Scoring Instrument to Predict the Survival Prognoses of Patients with Metastatic Epidural Spinal Cord Compression from Gynecological Malignancies. *Anticancer Research*, **2016**, 36, 5469-5472	2.3	1
297	Comparison of 20□2 Gy and 12□3 Gy for Whole-brain Irradiation of Multiple Brain Metastases from Malignant Melanoma. *In Vivo*, **2016**, 30, 917-919	2.3	5
296	Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck. *Anticancer Research*, **2016**, 36, 5463-5468	2.3	3
295	Prognostic Factors in Patients Irradiated for Recurrent Head-and-Neck Cancer. *Anticancer Research*, **2016**, 36, 6547-6550	2.3	1
294	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 255-64	7.3	272

293	Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma. *Radiology and Oncology*, **2016**, 50, 337-40	3.8	14
292	Robustness quantification methods comparison in volumetric modulated arc therapy to treat head and neck cancer. *Practical Radiation Oncology*, **2016**, 6, e269-e275	2.8	10
291	Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?. *Oral Oncology*, **2016**, 57, 40-5	4.4	8
290	A New Score for Estimating Survival After Definitive Radiochemotherapy of Limited Disease Small Cell Lung Cancers. *Lung*, **2016**, 194, 625-9	2.9	6
289	The effect of low hemoglobin levels on outcomes of radiotherapy following microscopically complete resection of locally advanced SCCHN: Implications for the future. *Journal of Cranio-Maxillo-Facial Surgery*, **2016**, 44, 1441-4	3.6	2
288	Personalized Radiotherapeutic Approaches for Elderly Patients with Epidural Cord Compression from Gastric Cancer. *In Vivo*, **2016**, 30, 69-72	2.3	2
287	Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma. *Anticancer Research*, **2016**, 36, 375-8	2.3	
286	Estimating the Survival of Elderly Patients with Renal Cell Carcinoma Presenting with Malignant Spinal Cord Compression. *Anticancer Research*, **2016**, 36, 409-13	2.3	1
285	Karnosky Performance Score and Radiation Dose Predict Survival of Patients Re-irradiated for a Locoregional Recurrence of Small Cell Lung Cancer. *Anticancer Research*, **2016**, 36, 803-5	2.3	3
284	A Survival Score for Patients Receiving Stereotactic Radiosurgery Alone for Brain Metastases from Breast Cancer. *Anticancer Research*, **2016**, 36, 1073-6	2.3	3
283	Impact of the Radiation Dose on Survival after Radiochemotherapy for Small-cell Lung Cancer. *Anticancer Research*, **2016**, 36, 1089-91	2.3	
282	Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer. *Anticancer Research*, **2016**, 36, 1825-8	2.3	6
281	Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly. *Anticancer Research*, **2016**, 36, 1829-33	2.3	2
280	Outcomes After Irradiation of Epidural Spinal Cord Compression Due to Metastatic Thyroid Cancer. *Anticancer Research*, **2016**, 36, 2035-9	2.3	6
279	Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer. *Anticancer Research*, **2016**, 36, 2487-91	2.3	1
278	Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer. *Anticancer Research*, **2016**, 36, 2523-6	2.3	2
277	A Total Radiation Dose of 70 Gy Is Required After Macroscopically Incomplete Resection of Squamous Cell Carcinoma of the Head and Neck. *Anticancer Research*, **2016**, 36, 2989-92	2.3	3
276	Potential Impact of the Overall Treatment Time on Outcomes after Whole-brain Irradiation with 10□ Gy for Brain Metastases. *Anticancer Research*, **2016**, 36, 3071-4	2.3	1

275	Radiation Therapy Alone Provides Excellent Outcomes for Spinal Cord Compression from Vertebral Lymphoma. *Anticancer Research*, **2016**, 36, 3081-3	2.3	1
274	Predicting the survival probability of gastric cancer patients developing metastatic epidural spinal cord compression (MESCC). *Gastric Cancer*, **2015**, 18, 881-4	7.6	4
273	A new tool predicting survival after radiosurgery alone for one or two cerebral metastases from lung cancer. *Lung*, **2015**, 193, 299-302	2.9	7
272	Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. *Practical Radiation Oncology*, **2015**, 5, e77-86	2.8	54
271	Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck. *BMC Cancer*, **2015**, 15, 102	4.8	2
270	A matched-pair analysis comparing 5x4 Gy and 10x3 Gy for metastatic spinal cord compression (MSCC) in patients with favorable survival prognoses. *Radiation Oncology*, **2015**, 10, 90	4.2	2
269	Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. *Journal of Geriatric Oncology*, **2015**, 6, 119-26	3.6	29
268	A new scoring system for predicting survival in patients with non-small cell lung cancer. *Cancer Medicine*, **2015**, 4, 1334-43	4.8	21
267	Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. *Journal of Thoracic Oncology*, **2015**, 10, 1099-106	8.9	33
266	Non-Small Cell Lung Cancer, Version 6.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 515-24	7.3	268
265	A new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from breast cancer. *Radiation Oncology*, **2015**, 10, 173	4.2	6
264	Number of cerebral lesions predicts freedom from new brain metastases after radiosurgery alone in lung cancer patients. *Oncology Letters*, **2015**, 10, 1109-1112	2.6	3
263	Single-Fraction Versus 5-Fraction Radiation Therapy for Metastatic Epidural Spinal Cord Compression in Patients With Limited Survival Prognoses: Results of a Matched-Pair Analysis. *International Journal of Radiation Oncology Biology Physics*, **2015**, 93, 368-72	4	15
262	Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncology, The*, **2015**, 16, 187-99	21.7	1200
261	International survey of the treatment of metastatic spinal cord compression. *Journal of Radiosurgery and SBRT*, **2015**, 3, 237-245	0.4	4
260	Pineal Tumors: Viewpoint Fractionated Radiation Therapy **2015**, 469-476		
259	Radiosurgery with 20 Gy provides better local contol of 1-3 brain metastases from breast cancer than with lower doses. *Anticancer Research*, **2015**, 35, 333-6	2.3	11
258	Predicting survival of patients with metastatic epidural spinal cord compression from cancer of the head-and-neck. *Anticancer Research*, **2015**, 35, 385-8	2.3	3

257	Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. *Anticancer Research*, **2015**, 35, 3571-4	2.3	12
256	Predicting Survival After Irradiation of Metastases from Pancreatic Cancer. *Anticancer Research*, **2015**, 35, 4105-8	2.3	5
255	Defining the Optimal Dose of Stereotactic Radiosurgery for Treating Cerebral Metastases in Elderly Patients. *Anticancer Research*, **2015**, 35, 5701-4	2.3	
254	A Tool to Estimate Survival of Elderly Patients Presenting with Metastatic Epidural Spinal Cord Compression (MESCC) from Cancer of Unknown Primary. *Anticancer Research*, **2015**, 35, 6219-22	2.3	3
253	Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. *Anticancer Research*, **2015**, 35, 6793-7	2.3	3
252	Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. *Lancet Oncology, The*, **2014**, 15, 1027-38	21.7	137
251	A validated score estimating ambulatory status following radiotherapy of elderly patients for metastatic spinal cord compression. *BMC Cancer*, **2014**, 14, 589	4.8	6
250	Stereotactic radiosurgery for newly diagnosed brain metastases: comparison of three dose levels. *Strahlentherapie Und Onkologie*, **2014**, 190, 786-91	4.3	10
249	Metastatic spinal cord compression: a validated survival score for elderly patients. *Strahlentherapie Und Onkologie*, **2014**, 190, 919-24	4.3	5
248	Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck. *Strahlentherapie Und Onkologie*, **2014**, 190, 1021-7	4.3	3
247	Non-small cell lung cancer, version 1.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 1738-61	7.3	130
246	Early Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Intra-Prostatic MRI Directed Boost. *OMICS Journal of Radiology*, **2014**, 3,	0	9
245	Do patients with very few brain metastases from breast cancer benefit from whole-brain radiotherapy in addition to radiosurgery?. *Radiation Oncology*, **2014**, 9, 267	4.2	5
244	Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma. *Journal of Dermatology*, **2014**, 41, 918-21	1.6	2
243	A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone. *Radiation Oncology*, **2014**, 9, 215	4.2	18
242	Prognostic role of the number of involved extraspinal organs in patients with metastatic spinal cord compression. *Clinical Neurology and Neurosurgery*, **2014**, 118, 12-5	2	12
241	Utilization of PSA measurement at three months following salvage radiation therapy to predict future biochemical outcome. *Journal of Radiation Oncology*, **2014**, 3, 81-87	0.7	
240	Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts. *Reviews in Urology*, **2014**, 16, 67-75	1	12

239	Proton beam therapy for locally advanced lung cancer: A review. *World Journal of Clinical Oncology*, **2014**, 5, 568-75	2.5	15
238	Metastatic spinal cord compression from pancreatic cancer. *Anticancer Research*, **2014**, 34, 3727-30	2.3	5
237	Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes. *Anticancer Research*, **2014**, 34, 5079-82	2.3	8
236	Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer. *Anticancer Research*, **2014**, 34, 5221-6	2.3	3
235	Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. *Anticancer Research*, **2014**, 34, 5589-92	2.3	4
234	Comparison of two dose levels of stereotactic radiosurgery for 1-3 brain metastases from non-small cell lung cancer. *Anticancer Research*, **2014**, 34, 7309-13	2.3	2
233	Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer. *Journal of Radiation Oncology*, **2013**, 2, 309-314	0.7	
232	A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. *Radiotherapy and Oncology*, **2013**, 108, 123-7	5.3	32
231	The first survival score for patients with brain metastases from small cell lung cancer (SCLC). *Clinical Neurology and Neurosurgery*, **2013**, 115, 2029-32	2	19
230	The number of involved extracranial organs: a new predictor of survival in breast cancer patients with brain metastasis. *Clinical Neurology and Neurosurgery*, **2013**, 115, 2108-10	2	6
229	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. *Lancet Oncology, The*, **2013**, 14, 619-26	21.7	141
228	Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. *Journal of Urology*, **2013**, 190, 521-6	2.5	35
227	Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 18-26	4	69
226	Re: Proton vs intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. *Journal of the National Cancer Institute*, **2013**, 105, 748	9.7	1
225	A score to identify patients with metastatic spinal cord compression who may be candidates for best supportive care. *Cancer*, **2013**, 119, 897-903	6.4	45
224	A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. *Journal of Thoracic Oncology*, **2013**, 8, 79-88	8.9	40
223	Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, **2013**, 143, e400S-e419S	5.3	223
222	A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. *Journal of Thoracic Oncology*, **2013**, 8, 1043-9	8.9	34

221	Locally Advanced Non-Small Cell Lung Cancer in the Elderly: What Combination of Therapy Is Best? **2013**, 173-183		
220	Use of thoracic radiation therapy for small-cell lung cancer **2013**, 114-128		
219	The prognostic impact of tumor cell expression of estrogen receptor-progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. *Cancer*, **2012**, 118, 157-63	6.4	38
218	Single brain metastasis: whole-brain irradiation plus either radiosurgery or neurosurgical resection. *Cancer*, **2012**, 118, 1138-44	6.4	15
217	Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. *Journal of Thoracic Oncology*, **2012**, 7, 919-22	8.9	41
216	Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 442-7	4	15
215	Risk of radiation retinopathy in patients with orbital and ocular lymphoma. *International Journal of Radiation Oncology Biology Physics*, **2012**, 84, 1145-50	4	40
214	Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. *Journal of Clinical Oncology*, **2012**, 30, 2788-97	2.2	185
213	Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancerA retrospective analysis. *Journal of Geriatric Oncology*, **2012**, 3, 104-110	3.6	8
212	Single brain metastasis: resection followed by whole-brain irradiation and a boost to the metastatic site compared to whole-brain irradiation plus radiosurgery. *Clinical Neurology and Neurosurgery*, **2012**, 114, 326-30	2	19
211	Prognostic factors for different outcomes in patients with metastatic spinal cord compression from cancer of unknown primary. *BMC Cancer*, **2012**, 12, 261	4.8	18
210	A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. *BMC Cancer*, **2012**, 12, 302	4.8	35
209	A new score predicting the survival of patients with spinal cord compression from myeloma. *BMC Cancer*, **2012**, 12, 425	4.8	14
208	Oropharyngeal cancer biology and treatment: insights from messenger RNA sequence analysis and transoral robotic surgery. *Mayo Clinic Proceedings*, **2012**, 87, 1132; author reply 1132-3	6.4	1
207	The clinical case for proton beam therapy. *Radiation Oncology*, **2012**, 7, 174	4.2	37
206	Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. *Prostate*, **2012**, 72, 1757-66	4.2	7
205	Single brain metastasis: radiosurgery alone compared with radiosurgery plus up-front whole-brain radiotherapy. *Cancer*, **2012**, 118, 2980-5	6.4	19
204	Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. *Cancer*, **2012**, 118, 3852-9	6.4	34

203	Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. *Cancer*, **2012**, 118, 5358-65	6.4	12
202	Malignant epidural spinal cord compression: the role of external beam radiotherapy. *Current Opinion in Supportive and Palliative Care*, **2012**, 6, 103-8	2.6	20
201	Radiation therapy modalities for prostate cancer. *JAMA - Journal of the American Medical Association*, **2012**, 308, 450-1; author reply 451-2	27.4	8
200	Small Cell Lung Cancer **2012**, 795-804		1
199	Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer - results of a matched-pair analysis. *European Journal of Cancer*, **2011**, 47, 2729-34	7.5	24
198	Surgery followed by radiotherapy versus radiotherapy alone for metastatic spinal cord compression from unfavorable tumors. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, e861-8	4	65
197	Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, e423-9	4	17
196	Shorter-course whole-brain radiotherapy for brain metastases in elderly patients. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, e469-73	4	18
195	Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 499-505	4	12
194	Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). *Strahlentherapie Und Onkologie*, **2011**, 187, 626-32	4.3	32
193	Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck: A matched-pair analysis. *Strahlentherapie Und Onkologie*, **2011**, 187, 541-7	4.3	15
192	Dose escalation of radiotherapy for metastatic spinal cord compression (MSCC) in patients with relatively favorable survival prognosis. *Strahlentherapie Und Onkologie*, **2011**, 187, 729-35	4.3	55
191	Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. *Cancer*, **2011**, 117, 1262-71	6.4	83
190	Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 524-30	4	139
189	Validation of a score predicting post-treatment ambulatory status after radiotherapy for metastatic spinal cord compression. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 1503-6	4	35
188	Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 1343-9	4	33
187	Scoring systems to estimate intracerebral control and survival rates of patients irradiated for brain metastases. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 1122-7	4	42
186	Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 1037-44	4	27

185	Dose escalation for metastatic spinal cord compression in patients with relatively radioresistant tumors. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 1492-7	4	22
184	Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. *Journal of Clinical Oncology*, **2011**, 29, 272-8	2.2	228
183	Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. *Journal of Clinical Oncology*, **2011**, 29, 279-86	2.2	267
182	Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. *Journal of Clinical Oncology*, **2010**, 28, 614-9	2.2	77
181	Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. *Journal of Clinical Oncology*, **2010**, 28, 3597-604	2.2	119
180	Treatment of painful bone metastases. *Nature Reviews Clinical Oncology*, **2010**, 7, 220-9	19.4	42
179	Short-course whole-brain radiotherapy (WBRT) for brain metastases due to small-cell lung cancer (SCLC). *Clinical Neurology and Neurosurgery*, **2010**, 112, 183-7	2	9
178	Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2010**, 33, 633-6	2.7	15
177	Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. *Journal of Thoracic Oncology*, **2010**, 5, 1346-53	8.9	27
176	Endpoints in phase II trials for advanced non-small cell lung cancer. *Journal of Thoracic Oncology*, **2010**, 5, 3-9	8.9	32
175	Dose escalation in patients receiving whole-brain radiotherapy for brain metastases from colorectal cancer. *Strahlentherapie Und Onkologie*, **2010**, 186, 70-75	4.3	21
174	Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. *Strahlentherapie Und Onkologie*, **2010**, 186, 218-23	4.3	29
173	Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC). *Strahlentherapie Und Onkologie*, **2010**, 186, 307-14	4.3	14
172	Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). *Strahlentherapie Und Onkologie*, **2010**, 186, 458-62	4.3	19
171	Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis. *Oral Oncology*, **2010**, 46, 549-52	4.4	5
170	Response to the comments on Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis *Oral Oncology*, **2010**, 46, 889-890	4.4	
169	Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. *BMC Cancer*, **2010**, 10, 582	4.8	27
168	The role of postoperative radiotherapy for the treatment of gangliogliomas. *Cancer*, **2010**, 116, 432-42	6.4	48

167	Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. *Cancer*, **2010**, 116, 3670-3	6.4	65
166	Reply to the Role of postoperative radiotherapy for the treatment of gangliogliomas. *Cancer*, **2010**, 116, 3071-3072	6.4	1
165	A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. *Cancer*, **2010**, 116, 5686-93	6.4	34
164	Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 735-40	4	88
163	Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 537-41	4	27
162	Hypofractionated whole-brain radiotherapy for multiple brain metastases from transitional cell carcinoma of the bladder. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 404-8	4	8
161	Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose?. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 398-403	4	18
160	Role of radiation therapy in the treatment of melanoma. *Expert Review of Anticancer Therapy*, **2009**, 9, 583-6	3.5	9
159	Prognostic factors for survival and intracerebral control after irradiation for brain metastases from gynecological cancer. *Gynecologic Oncology*, **2009**, 114, 506-8	4.9	6
158	Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. *Cancer*, **2009**, 115, 2721-31	6.4	87
157	Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. *Cancer*, **2009**, 115, 5596-606	6.4	36
156	Prostate brachytherapy seed embolization to the right renal artery. *Brachytherapy*, **2009**, 8, 309-12	2.4	22
155	Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. *Strahlentherapie Und Onkologie*, **2009**, 185, 675-81	4.3	41
154	Preliminary results of spinal cord compression recurrence evaluation (score-1) study comparing short-course versus long-course radiotherapy for local control of malignant epidural spinal cord compression. *International Journal of Radiation Oncology Biology Physics*, **2009**, 73, 228-34	4	82
153	A matched-pair analysis comparing whole-brain radiotherapy plus stereotactic radiosurgery versus surgery plus whole-brain radiotherapy and a boost to the metastatic site for one or two brain metastases. *International Journal of Radiation Oncology Biology Physics*, **2009**, 73, 1077-81	4	29
152	In Reply to Dr. Stojkovski. *International Journal of Radiation Oncology Biology Physics*, **2009**, 73, 1605	4	
151	Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2009**, 75, 1226-31	4	21
150	Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2009**, 75, 1364-70	4	17

149	In Reply to Belderbos et al.. *International Journal of Radiation Oncology Biology Physics*, **2009**, 74, 322-323	4	
148	Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: results of a matched pair analysis. *European Journal of Cancer*, **2009**, 45, 400-4	7.5	63
147	Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. *Journal of Thoracic Oncology*, **2009**, 4, 1075-82	8.9	50
146	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. *Mayo Clinic Proceedings*, **2008**, 83, 584-94	6.4	1313
145	Defining the role of hemithorax irradiation for thymomas is difficult. *Journal of Thoracic Oncology*, **2008**, 3, 1-2	8.9	2
144	A comparison of chemotherapy plus surgery with surgery alone for localized esophageal cancer. *Nature Clinical Practice Oncology*, **2008**, 5, 190-1		1
143	Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. *Mayo Clinic Proceedings*, **2008**, 83, 584-594	6.4	1919
142	Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases. *Strahlentherapie Und Onkologie*, **2008**, 184, 30-5	4.3	43
141	Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. *Strahlentherapie Und Onkologie*, **2008**, 184, 198-205	4.3	24
140	A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. *Strahlentherapie Und Onkologie*, **2008**, 184, 251-5	4.3	90
139	Impact of VEGF and VEGF receptor 1 (FLT1) expression on the prognosis of stage III esophageal cancer patients after radiochemotherapy. *Strahlentherapie Und Onkologie*, **2008**, 184, 416-20	4.3	14
138	Comparison of different treatment approaches for one to two brain metastases in elderly patients. *Strahlentherapie Und Onkologie*, **2008**, 184, 565-71	4.3	24
137	Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases. *Strahlentherapie Und Onkologie*, **2008**, 184, 655-62	4.3	47
136	Metastatic ependymoma: a multi-institutional retrospective analysis of prognostic factors. *Pediatric Blood and Cancer*, **2008**, 50, 231-5	3	49
135	The first score predicting overall survival in patients with metastatic spinal cord compression. *Cancer*, **2008**, 112, 157-61	6.4	106
134	Prognostic factors for functional outcome and survival after reirradiation for in-field recurrences of metastatic spinal cord compression. *Cancer*, **2008**, 113, 1090-6	6.4	64
133	Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. *Head and Neck*, **2008**, 30, 235-41	4.2	32
132	Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin. *International Journal of Radiation Oncology Biology Physics*, **2008**, 70, 1087-93	4	19

131	Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2008**, 70, 1108-14	4	60
130	Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis. *International Journal of Radiation Oncology Biology Physics*, **2008**, 70, 1319-24	4	41
129	The impact of tumor expression of erythropoietin receptors and erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 152-9	4	18
128	Effect of smoking during radiotherapy, respiratory insufficiency, and hemoglobin levels on outcome in patients irradiated for non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 1134-42	4	30
127	A score predicting posttreatment ambulatory status in patients irradiated for metastatic spinal cord compression. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, 905-8	4	65
126	Pineal Tumors: Fractionated Radiation Therapy Perspective **2008**, 371-376		
125	Lung cancer in the elderly. *Journal of Clinical Oncology*, **2007**, 25, 1898-907	2.2	116
124	Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. *Mayo Clinic Proceedings*, **2007**, 82, 490-513	6.4	105
123	Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. *Cancer*, **2007**, 109, 2515-21	6.4	85
122	The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. *Cancer*, **2007**, 110, 363-8	6.4	48
121	Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. *Cancer*, **2007**, 110, 1077-82	6.4	26
120	Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. *Cancer*, **2007**, 110, 1345-50	6.4	35
119	A boost in addition to whole-brain radiotherapy improves patient outcome after resection of 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. *Cancer*, **2007**, 110, 1551-9	6.4	34
118	A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. *Cancer*, **2007**, 110, 1791-5	6.4	61
117	Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. *Cancer*, **2007**, 110, 2285-92	6.4	72
116	Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. *Cancer*, **2007**, 110, 2587-92	6.4	31
115	Radiotherapy of metastatic spinal cord compression in very elderly patients. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 256-63	4	34
114	Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 532-7	4	33

113	Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 525-31	4	37
112	Central neurocytoma: management recommendations based on a 35-year experience. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 1145-54	4	106
111	Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 995-1001	4	11
110	Improved posttreatment functional outcome is associated with better survival in patients irradiated for metastatic spinal cord compression. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 1506-9	4	11
109	Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2007**, 68, 1053-8	4	102
108	Reduction of overall treatment time in patients irradiated for more than three brain metastases. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 1509-13	4	36
107	Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. *Oral Oncology*, **2007**, 43, 535-43	4.4	32
106	Radio(chemo)therapy plus resection versus radio(chemo)therapy alone for the treatment of stage III esophageal cancer. *Strahlentherapie Und Onkologie*, **2007**, 183, 10-6	4.3	16
105	Experiences with a new high-dose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer. *Strahlentherapie Und Onkologie*, **2007**, 183, 398-402	4.3	13
104	Whole-brain radiotherapy with 20 Gy in 5 fractions for brain metastases in patients with cancer of unknown primary (CUP). *Strahlentherapie Und Onkologie*, **2007**, 183, 631-6	4.3	23
103	Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*, **2007**, 132, 266S-276S	5.3	119
102	Is surgery necessary following chemoradiation for patients with locally advanced cancer of the esophagus?. *Nature Clinical Practice Oncology*, **2007**, 4, 506-7		6
101	Is stereotactic radiosurgery the best treatment option for patients with spinal metastases?. *Nature Clinical Practice Oncology*, **2007**, 4, 400-1		4
100	Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. *Journal of Clinical Oncology*, **2007**, 25, 50-6	2.2	74
99	Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). *Journal of Clinical Oncology*, **2007**, 25, 3124-9	2.2	52
98	Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. *Journal of Thoracic Oncology*, **2007**, 2, 751-7	8.9	43
97	D7-07: A phase II NCCTG Window of Opportunity Front-line study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC. *Journal of Thoracic Oncology*, **2007**, 2, S413	8.9	19
96	Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. *Mayo Clinic Proceedings*, **2007**, 82, 364-380	6.4	248

95	Do bladder cancer patients with metastatic spinal cord compression benefit from radiotherapy alone?. *Urology*, **2007**, 69, 1081-5	1.6	10
94	Spinal cord compression. *European Journal of Cancer, Supplement*, **2007**, 5, 359-370	1.6	1
93	Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. *Mayo Clinic Proceedings*, **2007**, 82, 364-80	6.4	270
92	Is 50 Gy sufficient to achieve long-term local control after incomplete resection of typical neurocytomas?. *Strahlentherapie Und Onkologie*, **2006**, 182, 415-8	4.3	12
91	Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: results of a retrospective multi-center study. *European Urology*, **2006**, 49, 846-52; discussion 852	10.2	19
90	Value of postoperative stereotactic radiosurgery and conventional radiotherapy for incompletely resected typical neurocytomas. *Cancer*, **2006**, 106, 1140-3	6.4	45
89	A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. *Cancer*, **2006**, 107, 781-92	6.4	91
88	Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. *Journal of Clinical Oncology*, **2006**, 24, 3388-93	2.2	252
87	Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. *Journal of Urology*, **2006**, 176, 985-90	2.5	91
86	Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. *Journal of Urology*, **2006**, 176, 2020-4	2.5	64
85	Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients. *European Journal of Cancer*, **2006**, 42, 1052-6	7.5	20
84	Innovations in the Radiotherapy of Non???Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2006**, 1, 85-92	8.9	6
83	Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials. *Journal of Thoracic Oncology*, **2006**, 1, 556-563	8.9	4
82	Innovations in the Radiotherapy of Non‐Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2006**, 1, 85-92	8.9	9
81	Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 182-8	4	54
80	Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 1452-7	4	50
79	Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study. *International Journal of Radiation Oncology Biology Physics*, **2006**, 65, 459-65	4	24
78	Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2006**, 65, 1106-11	4	102

77	Treatment recommendations for the various subgroups of neurocytomas. *Journal of Neuro-Oncology*, **2006**, 77, 305-9	4.8	64
76	Dose-response relationship for fractionated irradiation in the treatment of spinal meningeal melanocytomas: a review of the literature. *Journal of Neuro-Oncology*, **2006**, 77, 311-4	4.8	37
75	Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials. *Journal of Thoracic Oncology*, **2006**, 1, 556-563	8.9	11
74	Innovations in the radiotherapy of non-small cell lung cancer. *Journal of Thoracic Oncology*, **2006**, 1, 85-98	8.9	5
73	Dose-effect relationship for radiotherapy after incomplete resection of atypical neurocytomas. *Radiotherapy and Oncology*, **2005**, 74, 67-9	5.3	8
72	Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 60-3	4	15
71	The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2005**, 62, 1432-7	4	13
70	Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels. *Cancer*, **2005**, 103, 1740-6	6.4	22
69	Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. *Cancer*, **2005**, 103, 2349-54	6.4	61
68	Epoetin-alpha during radiotherapy for stage III esophageal carcinoma. *Cancer*, **2005**, 103, 2274-9	6.4	11
67	Well-differentiated neurocytoma: what is the best available treatment?. *Neuro-Oncology*, **2005**, 7, 77-83	1	60
66	Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. *Journal of Clinical Oncology*, **2005**, 23, 9113-9	2.2	101
65	Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. *Journal of Clinical Oncology*, **2005**, 23, 3366-75	2.2	267
64	Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, **2005**, 23, 5929-37	2.2	64
63	Prognostic value of the MIB-1 labeling index for central neurocytomas. *Neurology*, **2004**, 62, 987-9	6.5	68
62	Treatment of atypical neurocytomas. *Cancer*, **2004**, 100, 814-7	6.4	75
61	Therapy of meningeal melanocytomas. *Cancer*, **2004**, 100, 2442-7	6.4	65
60	A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. *Cancer*, **2004**, 101, 2687-92	6.4	76

59	Defining the best available treatment for neurocytomas in children. *Cancer*, **2004**, 101, 2629-32	6.4	22
58	Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 1530-5	4	21
57	Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2004**, 59, 943-51	4	129
56	Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2004**, 60, 24-9	4	25
55	Treatment planning for dose escalation in non-small cell lung cancer (NSCLC). *Medical Dosimetry*, **2004**, 29, 196-203	1.3	5
54	Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?. *Urology*, **2004**, 64, 760-4	1.6	39
53	Radiotherapy for a rising PSA following radical prostatectomy. *Urologic Oncology: Seminars and Original Investigations*, **2004**, 22, 57-61	2.8	2
52	Breast-conserving therapy and sentinel lymph node biopsy are feasible in cancer patients with previous implant breast augmentation. *American Journal of Surgery*, **2004**, 188, 122-5	2.7	46
51	Acute and chronic results of adjuvant radiotherapy after mastectomy and Transverse Rectus Abdominis Myocutaneous (TRAM) flap reconstruction for breast cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2004**, 27, 389-94	2.7	28
50	The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. *Journal of Clinical Oncology*, **2003**, 21, 3201-6	2.2	194
49	Endocavitary radiation therapy for rectal adenocarcinoma: 10-year results. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2003**, 26, 508-12	2.7	17
48	Rectal cancer: Preoperative versus postoperative irradiation as a component of adjuvant treatment. *Seminars in Radiation Oncology*, **2003**, 13, 419-32	5.5	12
47	In response to Drs. Kopelson et al. *International Journal of Radiation Oncology Biology Physics*, **2003**, 55, 282	4	
46	Defining the optimal dose of radiation after incomplete resection of central neurocytomas. *International Journal of Radiation Oncology Biology Physics*, **2003**, 55, 373-7	4	31
45	In response to Dr. Beitler. *International Journal of Radiation Oncology Biology Physics*, **2003**, 55, 1460-1461	4	
44	Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. *Journal of Urology*, **2003**, 170, 1833-7	2.5	55
43	O-238 The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. *Lung Cancer*, **2003**, 41, S70	5.9	6
42	Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience. *Journal of Surgical Oncology*, **2002**, 80, 19-25; discussion 26	2.8	99

41	Benign central neurocytoma: a double misnomer?. *Cancer*, **2002**, 94, 284	6.4	3
40	In regard to the radiotherapy of myxopapillary ependymomas. *International Journal of Radiation Oncology Biology Physics*, **2002**, 53, 787	4	22
39	Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2002**, 54, 370-8	4	87
38	Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2002**, 54, 729-34	4	5
37	Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2002**, 52, 167-75	4	129
36	Salvage radiotherapy for elevated PSA levels following prostatectomy. *Cancer Journal (Sudbury, Mass)*, **2002**, 8, 234-5	2.2	
35	Malignant pineal parenchymal tumors in adult patients: patterns of care and prognostic factors. *Neurosurgery*, **2002**, 51, 44-55; discussion 55-6	3.2	124
34	Radiation therapy (RT) after prostatectomy: The case for salvage therapy as opposed to adjuvant therapy. *International Journal of Cancer*, **2001**, 96, 94-8	7.5	26
33	The role of radiotherapy after radical prostatectomy. *Urologic Clinics of North America*, **2001**, 28, 629-37, x	2.9	6
32	Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma. *International Journal of Radiation Oncology Biology Physics*, **2000**, 46, 109-18	4	29
31	Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. *International Journal of Radiation Oncology Biology Physics*, **2000**, 46, 589-98	4	36
30	RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER. *Journal of Urology*, **2000**, 163, 845-850	2.5	173
29	RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER. *Journal of Urology*, **2000**, 845	2.5	3
28	Laparoscopic radical parametrectomy and pelvic and aortic lymphadenectomy for vaginal carcinoma: A case report. *Gynecologic Oncology*, **1999**, 75, 514-6	4.9	26
27	Metastatic spinal cord compression in patients with colorectal cancer. *Journal of Neuro-Oncology*, **1999**, 44, 175-80	4.8	39
26	The results of radiotherapy for brainstem tumors. *Journal of Neuro-Oncology*, **1998**, 40, 171-7	4.8	21
25	Radiation therapy after prostatectomy: now or later?. *Seminars in Radiation Oncology*, **1998**, 8, 132-9	5.5	29
24	Malignant peripheral nerve sheath tumor: analysis of treatment outcome. *International Journal of Radiation Oncology Biology Physics*, **1998**, 42, 351-60	4	315

23	The results of radiotherapy for ependymomas: the Mayo Clinic experience. *International Journal of Radiation Oncology Biology Physics*, **1998**, 42, 953-8	4	150
22	Radiation therapy for histologically confirmed primary central nervous system germinoma. *International Journal of Radiation Oncology Biology Physics*, **1997**, 38, 915-23	4	104
21	Stereotactic radiosurgery for glomus jugulare tumors: a preliminary report. *International Journal of Radiation Oncology Biology Physics*, **1997**, 38, 491-5	4	76
20	The role of retrograde urethrography in the planning of prostate cancer radiotherapy. *Medical Dosimetry*, **1997**, 22, 83-6	1.3	5
19	The treatment of locally advanced colon cancer. *International Journal of Radiation Oncology Biology Physics*, **1997**, 37, 51-8	4	33
18	Central neurocytomas. *Cancer*, **1997**, 79, 790-5	6.4	131
17	The Use of Radiotherapy for Patients with Isolated Elevation of Serum Prostate Specific Antigen Following Radical Prostatectomy. *Journal of Urology*, **1996**, 156, 1725-1729	2.5	109
16	Evaluation of serum prostate-specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer. *Mayo Clinic Proceedings*, **1996**, 71, 242-8	6.4	14
15	Analysis of outcome in patients reirradiated for brain metastases. *International Journal of Radiation Oncology Biology Physics*, **1996**, 34, 585-90	4	117
14	Histologically confirmed pineal tumors and other germ cell tumors of the brain. *Cancer*, **1996**, 78, 2564-70	6.4	122
13	Endocavitary radiotherapy of rectal cancer. *International Journal of Radiation Oncology Biology Physics*, **1996**, 34, 677-82	4	31
12	The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **1996**, 34, 535-41	4	75
11	Nongerminomatous germ cell tumors of the brain. *International Journal of Radiation Oncology Biology Physics*, **1996**, 36, 557-63	4	53
10	Regarding postoperative radiotherapy for pathologic stage C prostate cancer: In response to Dr. Lawrence and Mr. Collins. *International Journal of Radiation Oncology Biology Physics*, **1996**, 36, 757-758	4	
9	Tonsil cancer. Patterns of failure after surgery alone and surgery combined with postoperative radiation therapy. *Cancer*, **1994**, 73, 2638-47	6.4	39
8	Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. *Mayo Clinic Proceedings*, **1994**, 69, 613-9	6.4	62
7	Movements of the prostate due to rectal and bladder distension: implications for radiotherapy. *Medical Dosimetry*, **1993**, 18, 13-5	1.3	82
6	Pineal parenchymal tumors. Clinical, pathologic, and therapeutic aspects. *Cancer*, **1993**, 72, 870-80	6.4	198

5	Radiotherapy treatment planning for prostate cancer in patients with prosthetic hips. *Medical Dosimetry*, **1992**, 17, 83-6	1.3	14
4	Results of radiotherapy for chemodectomas. *Mayo Clinic Proceedings*, **1992**, 67, 537-40	6.4	63
3	The results of radiotherapy for isolated elevation of serum PSA levels following radical prostatectomy. *International Journal of Radiation Oncology Biology Physics*, **1992**, 23, 141-5	4	29
2	Long-term survival and patterns of failure after postoperative radiation therapy for subtotally resected rectal adenocarcinoma. *International Journal of Radiation Oncology Biology Physics*, **1989**, 16, 459-63	4	54
1	Postoperative adjuvant therapy of rectal cancer: an analysis of disease control, survival, and prognostic factors. *International Journal of Radiation Oncology Biology Physics*, **1989**, 17, 55-62	4	59